Company
Headquarters: Boston, MA, United States
$390.3 Million
USD as of July 1, 2024
Company | Market Cap (USD) |
---|---|
Blackstone | $148.37 B |
BlackRock | $117.48 B |
KKR & Co. Inc. | $97.78 B |
Brookfield Corporation | $65.40 B |
The Bank of New York Mellon Corporation | $44.78 B |
Company | Market Cap (USD) |
---|---|
Berkshire Hathaway | $887.16 B |
JPMorgan | $599.29 B |
Visa | $550.38 B |
Mastercard | $416.63 B |
Bank of America | $316.02 B |
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Tekla Life Sciences Investors has the following listings and related stock indices.
Stock: NYSE: HQL wb_incandescent